Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  Antibiotic resistance
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

Cross-resistance and associated resistance in Escherichia coli isolates from nosocomial urinary tract infections between 2004–2006 in a Turkish Hospital

100%
Ozyurt M., Oncul O., Ceylan S., Haznedaroglu T., Sahiner F., Ardic N.
Open Medicine
|
2008
|
vol. 3
|
issue 4
446-452
EN
In this study, antimicrobial resistance profiles were determined for 748 isolates of Escherichia coli from patients with acute nosocomial urinary tract infections (UTIs) at a Turkish Training Hospital. Thirteen antibiotics were included. Resistance to ampicillin alone (45.1%) and ciprofloxacin alone (20.6%) were the most commonly identified ‘single resistances’. Multiple resistance was found in 49.7% of the strains. The most common multiple antibiotic resistance profiles included ampicillin-sulbactam/amoxycilline-clavulonate (4.0%) and ampicillin-sulbactam/trimethoprim-sulfamethoxazole/amoxycilline-clavulonate (2.8%). From 2004 to 2006, ampicillin, trimethoprim-sulfamethoxazole and ciprofloxacin resistant strains increased to 76% from 57%, 53% from 43% and 55% from 41%, respectively. The percentage of extended-spectrum β-lactamase (ESBL) producing strains was 7.8% and imipenem resistance was seen in 5.2% of ESBL positive strains. We conclude that clinically important E.coli strains have now emerged with broader multidrug resistance. Periodical evaluation of laboratory results and clinical surveillance are crucially important for optimal antibiotic management of UTIs and infection control policies.
2
Publication available in full text mode
Content available

Curbing Antimicrobial Resistance, for Better Development in the Health and Public Sector

88%
Njoku P. C., Ezeumeh I. E., Shehu A., Fayemi O. O., Faniyi A. J., Akinlalu A. O., Olagunju A. S.
World News of Natural Sciences
|
2023
|
vol. 47
14-27
EN
With 1.27 million deaths in 2019, antimicrobial resistance (AMR) has resulted in the deaths of more people than HIV/AIDS and malaria combined. AMR is listed among the top 10 global public health priorities by the WHO. The magnitude of the AMR burden is poorly prioritized in the public health sector, and its impact is difficult to accurately estimate due to a lack of sufficient data, especially in Africa. The misuse and overuse of antibiotics for various non-medical purposes is widely reported, especially in low-income developing countries, as one of the key contributors to AMR, yet little effort is put in place to curb the menace. Also, the clinical pipeline of new antimicrobials is scanty. This review explores the mechanism of AMR, the effects of AMR on health and the public sector with regard to morbidity, mortality, and economic losses, and the impact of COVID-19 on AMR. Recent potential therapies that are used to combat AMR, such as phage therapy, and how they could bring about development in the public health sector were discussed. Also, the impact of vaccines and preventive strategies to curb the spread of AMR in the public sector were highlighted.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.